![Prof-Thomas-banner](/sg/sites/default/files/2024-03/Prof-Thomas-banner.jpg)
JARDIANCE® provides triple protection in your patients with CRM conditions:
![Prof-merlin-keyfact1 Prof-merlin-keyfact1](/sg/sites/default/files/2024-03/Prof-merlin-keyfact1.png)
reduced risk of CV death
or kidney disease progression*1,2
![Prof-merlin-keyfact2 Prof-merlin-keyfact2](/sg/sites/default/files/2024-03/Prof-merlin-keyfact2.png)
reduced risk of CV death
or hospitalisation for heart failure†3,4
![Prof-merlin-keyfact3 Prof-merlin-keyfact3](/sg/sites/default/files/2024-03/Prof-merlin-keyfact3.png)
reduced risk of CV death‡5
How do you interpret the importance of EMPA-KIDNEY results with regards to the treatment of patients with CKD?
01/04/2024 | Author: Boehringer Ingelheim
Document ID: PC-SG-102387